Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Pharmacokinetic Study of Antiviral Drugs in Patients with COVID-19
Irie, K., Yakugaku Zasshi, doi:10.1248/yakushi.22-00169-1 (Dosing)
Irie, Pharmacokinetic Study of Antiviral Drugs in Patients with COVID-19, , K., Yakugaku Zasshi, doi:10.1248/yakushi.22-00169-1 (Dosing)
Mar 2023   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Pharmacokinetics study measuring the blood concentration of favipiravir in 7 critical patients in Japan, showing concentrations below the EC50 in 33 of 36 samples when using the standard dosing regimen. Authors note that patient characteristics significantly affect concentrations - there is higher clearance with increased body surface area and with the use of ventilation.
Irie et al., 1 Mar 2023, Japan, peer-reviewed, 1 author.
Contact: kei_irie@pharm.kobegakuin.ac.jp.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: YAKUGAKU ZASSHI 143, 239–241 (2023) Vol. 143, No. 3 239 — Symposium Review — COVID-19 患者における抗ウイルス薬の薬物動態研究 入江 慶 Pharmacokinetic Study of Antiviral Drugs in Patients with COVID-19 Kei Irie Faculty of Pharmaceutical Science, Kobe Gakuin University, 1–1–3 Minatojima, Chuo-ku, Kobe 650–8586, Japan. (Received August 12, 2022) The Faculty of Pharmaceutical Sciences, Kobe Gakuin University has collaborated in clinical research with Kobe City Medical Center General Hospital. In this university–medical institution collaboration, university faculty members discuss clinical problems with on-site pharmacists and doctors, and carry out clinical research to resolve these problems. During the coronavirus disease 2019 (COVID-19) pandemic, many patients with COVID-19 were treated at Kobe City Medical Center General Hospital. In February 2020, during the first increase in the number of patients with COVID-19 in Japan, treatment for COVID-19 was not established, and some existing anti-viral drugs, such as favipiravir, were experimentally used for COVID19 treatment. However, since these drugs were not developed specifically for treating COVID-19, their pharmacokinetics have not been sufficiently studied. In particular, the pharmacokinetics of favipiravir in critically ill patients with COVID-19 was of concern, because critically ill patients have an urgent need for life-saving anti-viral drug treatment. Therefore, we conducted a collaborative clinical study to evaluate the pharmacokinetics of favipiravir in patients with COVID-19. The blood concentration of favipiravir in patients with COVID-19 at Kobe City Medical Center General Hospital was measured by lipid chromatography-tandem mass spectrometry at Kobe Gakuin University. Population pharmacokinetics analysis was then performed. In this symposium review, we introduce our pharmacokinetic study of antiviral drugs in patients with COVID-19, focusing on the university–medical institution collaboration. We believe collaborative clinical research will be useful for solving clinical issues and ensuring the effectiveness and safety of pharmacotherapies. Key words 1. collaborative clinical study, pharmacokinetics, anti-viral drug, favipiravir, coronavirus disease 2019 (COVID-19) 大学医療連携の取り組み に関する問題について,大学の持つ測定技術や解析 神戸学院大学薬学部では, 近隣の医療機関と教 技術を駆使し,共同で臨床研究を実施することによ 育・研究を協力し行う大学医療連携活動を行ってい り,薬物治療の有効性や安全性を向上できる.本稿 る.特に同じ神戸医療産業都市(ポートアイランド では,薬学を基盤とした基礎と臨床の融合研究(臨 内)に位置する神戸市立医療センター中央市民病院 床現場の問題を,大学が協力し,臨床研究で解決) とは,2011 年に「教育・研究協力に関する協定」を の例として,新型コロナウイルス感染症(coronavi- 締結し,密な連携により教育・研究を共同して行っ rus disease 2019: COVID-19)患者における抗ウイル ている.同病院において大学教員が若手薬剤師の行 ス薬の薬物動態研究について紹介する. 新型コロナウイルス感染症(COVID-19) う臨床研究の指導を行ったり,薬学部の学生の卒業 2. 研究として,臨床現場の問題をテーマに取り組んで 2019 年12月に中国武漢のアウトブレイクから始 いる.さらに,臨床現場の問題について大学教員と まったCOVID-19のパンデミックは,mRNAワクチン 医師や薬剤師と議論し,それを解決するための臨床 やいくつかの治療薬が開発された2022 年 8月において 研究を共同で実施している. 臨床現場の薬物治療 もいまだ続いており,その社会的な影響は非常に大き い.日本において,感染が拡大し始めたのは 2020 年 神戸学院大学薬学部(〒650–8586 神戸市中央区港島 1–1–3) e-mail: kei_irie@pharm.kobegakuin.ac.jp 本総説は, 日本薬学会第 142 年会シンポジウム S03 で 発表した内容を中心に記述したものである. 2月頃であり, クル ー ズ船におけるクラスタ ー が ニュースになり,また国内の感染者は日に日に増加し ていった.2020 年 4 月には,緊急事態宣言が発令され ることとなり,われわれの日常生活も大きく変化した. © 2023 The Pharmaceutical Society of Japan 240 Vol. 143, No. 3 (2023) YAKUGAKU ZASSHI 一方で,神戸市立医療センター中央市民病院では, ついて随時,議論をしている.ファビピラビルの問 感染症指定医療機関として, 多くの COVID-19 患者 題についても,COVID-19..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit